Precose Given FDA Clearance for Combination Therapy
The Food and Drug Administration has given marketing clearance to Bayer Corporation's pharmaceutical division to use Precose in combination with insulin or metformin for treating people with type 2 diabetes.
Precose, which is also known as acarbose, is an oral agent that works in the small intestine by delaying carbohydrate digestion and glucose absorption.
According to news wire reports, the FDA has given clearance for the use of Precose for people with type 2 diabetes whose postmeal blood sugars and long-term HbA1cs are not adequately controlled by insulin or metformin (also known as Glucophage).
"The UKPDS clearly indicates that the use of a single medication to control blood glucose levels and complications associated with diabetes may be inadequate," says James Magner, MD, deputy director of metabolics, Bayer pharmaceutical division. "Precose can be used safely in combination therapy with minimal side effects. We see this as being key to the future of diabetes management."
Common side effects associated with taking Precose include flatulence, abdominal pain and diarrhea.Click Here To View Or Post Comments